Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Public ClinicalTrials.gov record NCT05263206. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale \[WI-NRS ≥7) will enter a 4-week run-in period and will be treated with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS ≥7) at baseline will be randomized (1:1) to be treated for 24 weeks with either dupilumab or matching placebo in addition to their non-sedative antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.
Study identification
- NCT ID
- NCT05263206
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 284 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2022
- Primary completion
- Jun 1, 2027
- Completion
- Aug 24, 2027
- Last update posted
- Jul 5, 2026
2022 – 2027
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kern Allergy and Medical Research- Site Number : 8400016 | Bakersfield | California | 93301 | Completed |
| Modena Allergy + Asthma- Site Number : 8400038 | La Jolla | California | 92037 | Recruiting |
| FoxHall Dermatology- Site Number : 8400042 | Washington D.C. | District of Columbia | 20016 | Recruiting |
| Palm Harbor Dermatology- Site Number : 8400024 | Belleair | Florida | 32756 | Recruiting |
| University of Miami Hospital- Site Number : 8400011 | Miami | Florida | 33136 | Recruiting |
| Skin Care Physicians of Georgia - Macon- Site Number : 8400030 | Macon | Georgia | 31217 | Recruiting |
| Aeroallergy Research Laboratory- Site Number : 8400036 | Savannah | Georgia | 31406 | Recruiting |
| Dawes Fretzin Clinical Research- Site Number : 8400007 | Indianapolis | Indiana | 46256 | Recruiting |
| Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400031 | Louisville | Kentucky | 40241 | Recruiting |
| Tulane University School of Medicine- Site Number : 8400045 | New Orleans | Louisiana | 70112 | Recruiting |
| Johns Hopkins Hospital- Site Number : 8400020 | Baltimore | Maryland | 21287 | Recruiting |
| The Asthma and Allergy Center- Site Number : 8400014 | Bellevue | Nebraska | 68123 | Recruiting |
| Mount Sinai - Union Square- Site Number : 8400034 | New York | New York | 10003 | Recruiting |
| AXIS Clinicals - Fargo- Site Number : 8400037 | Fargo | North Dakota | 58103 | Recruiting |
| Optima Research - Boardman- Site Number : 8400039 | Boardman | Ohio | 44512 | Recruiting |
| Columbia Dermatology & Aesthetics- Site Number : 8400047 | Columbia | South Carolina | 29212 | Recruiting |
| National Allergy and Asthma - North Charleston - Northside Drive- Site Number : 8400032 | North Charleston | South Carolina | 29420 | Recruiting |
| Complete Dermatology - Sugar Land- Site Number : 8400046 | Sugar Land | Texas | 77479 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05263206, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05263206 live on ClinicalTrials.gov.